{"nctId":"NCT02486406","briefTitle":"A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects","startDateStruct":{"date":"2015-10-28","type":"ACTUAL"},"conditions":["Chronic Hepatitis C Infection"],"count":64,"armGroups":[{"label":"Adult tablet, 12-17 yr, Part 1","type":"EXPERIMENTAL","interventionNames":["Drug: Ombitasvir/paritaprevir/ritonavir","Drug: Dasabuvir","Drug: Ribavirin"]},{"label":"Adult tablet, 12-17 yr, Part 2","type":"EXPERIMENTAL","interventionNames":["Drug: Ombitasvir/paritaprevir/ritonavir","Drug: Dasabuvir","Drug: Ribavirin"]},{"label":"Mini tablet, 9-11 yr, Part 1","type":"EXPERIMENTAL","interventionNames":["Drug: Ombitasvir mini tablet","Drug: Paritaprevir mini tablet","Drug: Ritonavir mini tablet","Drug: Dasabuvir mini tablet","Drug: Ribavirin solution"]},{"label":"Mini tablet, 3-8 yr, Part 1","type":"EXPERIMENTAL","interventionNames":["Drug: Ombitasvir mini tablet","Drug: Paritaprevir mini tablet","Drug: Ritonavir mini tablet","Drug: Dasabuvir mini tablet","Drug: Ribavirin solution"]}],"interventions":[{"name":"Ombitasvir/paritaprevir/ritonavir","otherNames":["Ombitasvir also known as ABT-267","Paritaprevir also known as ABT-450","Ombitsvir/paritaprevir/ritonavir also known as Viekirax"]},{"name":"Dasabuvir","otherNames":["Exviera","ABT-333"]},{"name":"Ribavirin","otherNames":[]},{"name":"Ombitasvir mini tablet","otherNames":["ABT-267"]},{"name":"Paritaprevir mini tablet","otherNames":["ABT-450"]},{"name":"Ritonavir mini tablet","otherNames":[]},{"name":"Dasabuvir mini tablet","otherNames":["Exviera","ABT-333"]},{"name":"Ribavirin solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Positive anti-hepatitis C virus antibody (HCV Ab) and HCV ribonucleic acid (RNA) ≥ 1000 IU/mL at the time of screening\n2. HCV genotype 1 for enrollment into Part 1 of the study and genotype 1 or 4 for enrollment into Part 2\n3. Parent or legal guardian with the willingness and ability to provide written informed consent and participant willing and able to give assent, as appropriate for age and country\n\nExclusion Criteria:\n\n1. Female participant who is pregnant, breastfeeding or is considering becoming pregnant\n2. Use of known strong inducers and inhibitors (e.g., gemfibrozil) of cytochrome P450 2C8 (CYP2C8) in participants receiving dasabuvir, or strong or moderate inducers of CYP3A, within 2 weeks or 10 half-lives, whichever is longer, of the respective medication/supplement prior to study drug administration.\n3. Positive test result for Hepatitis B surface antigen (HbsAg) or anti-human immunodeficiency virus antibody (HIV Ab) test\n4. Current enrollment in another interventional clinical study, previous enrollment in this study, prior or current use of any investigational or commercially available anti-HCV agents other than interferons or ribavirin or receipt of any investigational product within 6 weeks prior to study drug administration","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV)","description":"Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":"27"},{"groupId":"OG001","value":"116","spread":"14"},{"groupId":"OG002","value":"83.7","spread":"39"}]}]}]},{"type":"PRIMARY","title":"Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ombitasvir (OBV)","description":"AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ombitasvir present was measured up to 24 hours after dosing.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1270","spread":"26"},{"groupId":"OG001","value":"1490","spread":"12"},{"groupId":"OG002","value":"1060","spread":"43"}]}]}]},{"type":"PRIMARY","title":"Part 1: Lowest Plasma Concentration (Ctrough) of Ombitasvir (OBV)","description":"Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.7","spread":"32"},{"groupId":"OG001","value":"28.2","spread":"16"},{"groupId":"OG002","value":"21.8","spread":"39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":"78"},{"groupId":"OG001","value":"30.4","spread":"24"},{"groupId":"OG002","value":"20.9","spread":"58"}]}]}]},{"type":"PRIMARY","title":"Part 1: Maximum Plasma Concentration (Cmax) of Paritaprevir (PTV)","description":"Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"294","spread":"152"},{"groupId":"OG001","value":"1540","spread":"71"},{"groupId":"OG002","value":"870","spread":"125"}]}]}]},{"type":"PRIMARY","title":"Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Paritaprevir (PTV)","description":"AUC is a measure of how long and how much drug is present in the body after dosing. The amount of paritaprevir present was measured up to 24 hours after dosing.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2180","spread":"136"},{"groupId":"OG001","value":"8640","spread":"90"},{"groupId":"OG002","value":"5770","spread":"152"}]}]}]},{"type":"PRIMARY","title":"Part 1: Lowest Plasma Concentration (Ctrough) of Paritaprevir (PTV)","description":"Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.86","spread":"113"},{"groupId":"OG001","value":"16.1","spread":"112"},{"groupId":"OG002","value":"18.0","spread":"78"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":"136"},{"groupId":"OG001","value":"18.4","spread":"89"},{"groupId":"OG002","value":"23.5","spread":"86"}]}]}]},{"type":"PRIMARY","title":"Part 1: Maximum Plasma Concentration (Cmax) of Dasabuvir (DSV)","description":"Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"579","spread":"44"},{"groupId":"OG001","value":"830","spread":"45"},{"groupId":"OG002","value":"671","spread":"48"}]}]}]},{"type":"PRIMARY","title":"Part 1: Concentration of Drug in Blood Plasma Against Time [Area Under the Curve (AUC)] of Dasabuvir (DSV)","description":"AUC is a measure of how long and how much drug is present in the body after dosing. The amount of dasabuvir present was measured up to 12 hours after dosing. For two subjects in the 15-29 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation. For one subject in the 30-44 kg group, the 24 h concentration was used as the 12 h concentration due to the significant sampling time deviation.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3960","spread":"44"},{"groupId":"OG001","value":"5960","spread":"47"},{"groupId":"OG002","value":"4630","spread":"49"}]}]}]},{"type":"PRIMARY","title":"Part 1: Lowest Plasma Concentration (Ctrough) of Dasabuvir (DSV)","description":"Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":"57"},{"groupId":"OG001","value":"215","spread":"54"},{"groupId":"OG002","value":"165","spread":"56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"168","spread":"82"},{"groupId":"OG001","value":"264","spread":"65"},{"groupId":"OG002","value":"191","spread":"60"}]}]}]},{"type":"PRIMARY","title":"Part 1: Maximum Plasma Concentration (Cmax) of Ritonavir (RTV)","description":"Cmax is the peak concentration that a drug or drug metabolite achieves in a specified compartment after the drug has been administrated and before administration of a second dose.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1090","spread":"67"},{"groupId":"OG001","value":"1830","spread":"42"},{"groupId":"OG002","value":"1180","spread":"35"}]}]}]},{"type":"PRIMARY","title":"Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ritonavir (RTV)","description":"AUC is a measure of how long and how much drug is present in the body after dosing. The amount of ritonavir present was measured up to 24 hours after dosing.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6570","spread":"60"},{"groupId":"OG001","value":"14100","spread":"49"},{"groupId":"OG002","value":"8900","spread":"37"}]}]}]},{"type":"PRIMARY","title":"Part 1: Lowest Plasma Concentration (Ctrough) of Ritonavir (RTV)","description":"Minimum plasma concentration (Ctrough; measured in ng/mL) was directly determined from the concentration-time data.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.1","spread":"72"},{"groupId":"OG001","value":"32.1","spread":"63"},{"groupId":"OG002","value":"29.8","spread":"54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":"268"},{"groupId":"OG001","value":"38.1","spread":"112"},{"groupId":"OG002","value":"58.2","spread":"138"}]}]}]},{"type":"PRIMARY","title":"Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12)","description":"SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \\< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12) Summarized by Formulation, Age and Weight Group, and Across All Subjects on the Adult Formulations","description":"SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \\< lower limit of quantification (LLOQ) 12 weeks after the last actual dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null},{"groupId":"OG004","value":"92.9","spread":null},{"groupId":"OG005","value":"96.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 & 2: Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Actual Dose of Study Drug (SVR24), Summarized by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations","description":"SVR24 is defined as hepatitis C virus ribonucleic acid (HCV RNA) \\< lower limit of quantification (LLOQ) 24 weeks after the last actual dose of study drug.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.9","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100.0","spread":null},{"groupId":"OG003","value":"88.9","spread":null},{"groupId":"OG004","value":"100.0","spread":null},{"groupId":"OG005","value":"92.9","spread":null},{"groupId":"OG006","value":"92.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Parts 1 and 2: Percentage of Participants With Alanine Aminotransferase (ALT) Normalization During Treatment by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations","description":"Alanine aminotransferase (ALT) normalization during treatment is defined as ALT ≤ the upper limit of normal (ULN) at the final treatment visit for participants with ALT \\> ULN at baseline.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"80.0","spread":null},{"groupId":"OG004","value":"87.5","spread":null},{"groupId":"OG005","value":"87.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Headache","Fatigue","Pyrexia","Nasopharyngitis","Upper respiratory tract infection"]}}}